Iranian Scientists Review Performance of Drug Inhibitors in Treatment of Colorectal Cancer
“Inflammatory bowel diseases (IBD) are a group of chronic diseases of the digestive system that lead to damage and inflammation of the colon and other parts of the digestive system. The two main types of this disease include Crohn's disease and ulcerative colitis; intestinal inflammation in colitis can lead to a type of colon cancer,” said Maryam Moradi Binabaj, a PhD student in clinical biochemistry from Mashhad University of Medical Sciences.
“In this research, the therapeutic potential of the drug inhibitor EW 7197 was studied in the murine model of inflammatory colitis and the cell and animal model of colorectal cancer,” she added.
Moradi Binabaj explained that in the colitis phase, after the creation of the colitis model and the treatment of mice, tissues and blood samples were examined and the mice were used to investigate the effect of drug inhibitor EW-7197 on reducing the pathological symptoms of inflammatory colitis.
Colon cancer is a growth of cells that begins in a part of the large intestine called the colon. The colon is the first and longest part of the large intestine. The large intestine is the last part of the digestive system. The digestive system breaks down food for the body to use.
Colon cancer typically affects older adults, though it can happen at any age. It usually begins as small clumps of cells called polyps that form inside the colon. Polyps generally aren't cancerous, but some can turn into colon cancers over time.
Polyps often don't cause symptoms. For this reason, doctors recommend regular screening tests to look for polyps in the colon. Finding and removing polyps helps prevent colon cancer.
4155/v
